64 results about "Xanthohumol" patented technology

The invention provides a method for extracting xanthohumol from hop and an obtained product thereof. The method mainly comprises the following steps: pulverized hop is extracted through supercritical carbon dioxide; a hop raffinate is collected and is subjected to ultrasonic extraction through methanol (ethanol) as an extractant; an extraction solution is condensed, is evenly mixed with diatomite and is successively eluted by two kinds of eluants; and the collected eluant is subjected to filtering and low-temperature condensation treatment to obtain the pure xanthohumol product. The purity of the obtained xanthohumol is 86.2 percent. The purified xanthohumol is a yellow powdery solid; and after the purified xanthohumol is recrystallized, the purity can reach over 97.8 percent. The method can achieve the functions of simplifying the xanthohumol extraction process and reducing the cost for purifying the xanthohumol. The obtained xanthohumol can be widely used in medicine, chemical engineering, food and other fields.

In a process for preparing a xanthohumol-enriched hop extract, a concentrate having contents of up to 90% xanthohumol is obtained from a xanthohumol-containing hop raw material by dissolving the xanthohumol in lye and subsequent precipitation with acid.

The present invention features therapeutic and prophylactic compositions comprising xanthohumol and/or xanthohumol/cyclodextrin complexes and methods of using such compositions for treating a skin condition, disease, or disorder.

The invention discloses an antagonistic drug against replication of a porcine reproductive and respiratory syndrome virus (PRRSV) and application of the antagonistic drug. A virus infection test is adopted, and Xanthohumol (Xn), the antagonistic drug of the PRRSV, is discovered for the first time from a natural medicine library with 386 plant sources. The drug can effectively inhibit PRRSV replication in both Marc-145 and PAM cells, five xanthohumol derivatives with different molecular structures are artificially synthesized, and the viral infection test further finds that the inhibition effect to virus replication by drug derivative Xn-4 is highest in vitro; and test results of artificial infection and drug therapy in piglets show that the Xn-4 can effectively inhibit PRRSV viremia, relieves clinical symptoms of infected pigs, and significantly reduces pulmonary inflammation and pathological damage. Combined with the results, it is proved that the antagonistic drug has important preventive and therapeutic effects to a porcine reproductive and respiratory syndrome, and has important application prospects.

The invention discloses application of xanthohumol to preparation of anti-porcine epidemic diarrhea virus medicine. The mass percent of the xanthohumol is larger than or equal to 99.75%, and the application dose of the xanthohumol is 1 microns/L to 10 microns/L; the effect of the xanthohumol on an anti-porcine epidemic diarrhea virus is quite remarkable, and the xanthohumol is safe, small in toxicand side effects, low in medicine residue and free of pollution.

According to the present invention, there is provided a medicament for oral administration or intravenous administration that is effective for a disease requiring enhancement of nerve growth factor production, comprising as an effective ingredient a pulverized product and/or extract obtained from Humulus lupulus and/or Angelica keiskei koidz., or xanthohumol and/or a pharmacologically acceptable salt thereof. The medicament is useful as a therapeutic agent or prophylactic agent for a disease requiring enhancement of nerve growth factor production, such as dementia or a nerve disorder. Also, according to the present invention, there are provided an enhancing agent for nerve growth factor production, and a food, beverage or feed for enhancing nerve growth factor production, each comprising the above effective ingredient. By taking the food or beverage as foodstuff on a daily basis, the symptoms of a disease requiring enhancement of nerve growth factor production can be ameliorated or the like. In addition, the feed is useful for maintaining homeostasis of a living body by its action of enhancing nerve growth factor production. Furthermore, these medicament and the like of the present invention are effective for improving or ameliorating learning and memorizing ability of an individual organism.

The invention provides use of xanthohumol in the prevention and treatment of acute lung injury and acute respiratory distress syndrome. The xanthohumol can be used for preventing and treating the acute lung injury and the acute respiratory distress syndrome. By treating the acute lung injury or the acute respiratory distress syndrome by virtue of xanthohumol, the toxic and side effects are small, clinical symptoms are obvious, and the curing rate is high.

The invention discloses a method for extracting xanthohumol in hop residue by supercritical CO2 technology, and relates to hop technology. The method comprises the following steps: taking raffinate (the hop residue) after alpha acid is extracted from hop by supercritical CO2 as a main raw material, adopting the supercritical CO2 technology, taking ethanol or methanol as an entrainer, and obtaining coarse xanthohumol; performing concentration and spray drying to obtain a coarse product of xanthohumol; and purifying to obtain a high-purity xanthohumol product. The method utilizes the raffinate after alpha acid is extracted from hop by supercritical CO2, and belongs to resource recycling. The method has simple process; the obtained xanthohumol product has good characteristics of high activity and good dissolubility; and the technological process is environment-friendly.

The invention relates to a method for extracting and separating xanthohumol and flavone compounds. The method comprises the following steps of: leaching hops and a supercritical CO2 extraction residue thereof with an alcohol solution to ensure that flavone compounds, particularly xanthohumol, are sufficiently dissolved out; filtering to obtain a filter liquor after leaching, and decompressing anddistilling the filter liquor to obtain a concentrated liquor; centrifuging the concentrated liquor, taking an obtained supernate, and filtering by using a 0.45muL of organic film; removing partial impurities, and eluting with an eluant to elute the flavone compounds from macroporous adsorption resin; collecting effluent liquid and concentrating; and freezing and drying to obtain yellow powder. In the invention, the hops, the supercritical CO2 extraction residue, and the like are used as raw materials, particularly, a waste material which is the supercritical CO2 hop extract extraction residuein a hop product processing process is used as the raw material, thus the xanthohumol which has the main efficacy and is difficult to separate is independently extracted, and other flavone compounds rich in the hop waste material are also extracted; and the invention also provides a development approach for hops which cannot be used for beer brewing, thereby improving the resource utilization ratio and the added value of the hops and having important significance to prolonging the hop industrial chain.

The invention discloses application of xanthohumol as an inhibitor of abnormal aggregation of Tau proteins to the preparation of a drug for preventing/treating a Tau protein disease or a functional food or health care product for preventing/alleviating the Tau protein disease. The invention discloses that xanthohumol has an effect of effectively inhibiting the abnormal aggregation function of Tauproteins, so that the pathological process of the Tau protein disease can be prevented, and meanwhile, since xanthohumol is non-toxic, xanthohumol can be used as an anti-Tau protein disease drug for the treatment of neurodegenerative diseases.

The invention belongs to the technical field of biology, and especially relates to a method for preparing xanthohumol from European hop spike. The method is characterized in that an European hop spike medicine material is crushed; 5-10 time amount of 50-70% ethanol is added for carrying out warm-soaking extraction 2-3 times; ethanol in an obtained extraction liquid is recovered, and the extraction liquid is filtered in an ultrafiltration membrane system; a permeate is concentrated in a nano-filtration membrane system; the concentrate is absorbed by using polyamide resin; 5-8 time amount of 15-25% ethanol is used for eluting; the elution liquid is concentrated into a paste; dehydrated ethanol is added for reflux dissolving; refrigeration crystallization is carried out; and a crystalline material is dried, such that xanthohumol is prepared. The method provided by the invention has the advantages of simple process, easy operation, low energy consumption during the production process, low pollution, and safe quality of obtained product. The product can be directly used in productions of foodstuffs and medicines.

The present invention provides methods of treating prostate cancer and benign prostatic hyperplasia using xanthohumol and/or a xanthohumol analog.

The invention relates to a natural plant pigment and a preparation method thereof, belonging to the field of extraction and application of natural products. The preparation method comprises the following steps: by using humulus lupulus or waste humulus lupulus residues generated in the humulus lupulus working process as a raw material, extracting and separating to obtain a yellow extract of which the main active component is xanthohumol; and purifying the extract to obtain the xanthohumol yellow crystal or powder. The crystal or powder is insoluble or slightly soluble in water. In order to widen the application range, cyclodextrin is utilized to include the crystal or powder to obtain the xanthohumol cyclodextrin inclusion compound which is applicable to beer, medicine, food proportioning, beverage proportioning, health-care tea proportioning, cosmetics and dye industry.

The invention belongs to the technical field of medicine, and particularly relates to application of xanthohumol and derivatives thereof in preparing drug for preventing or treating neurogenerative disease, especially for Alzheimer's disease. The inventor verifies that xanthohumol and the derivatives can remarkably lower Abeta1-40/42 concentration to inhibit Abeta gathering, can inhibit Tau protein phosphorylation by inhibiting CDK-5 activity and can serve as drug for treating potential neurogenerative disease like Alzheimer's disease to be further developed and utilized through Alzheimer's disease transgenic cells.